FDA approved a New breakthrough therapy ”Trikafta” for cystic fibrosis

For our Sofi comes this drug too late, but for other cystic fibrosis patients it is a new hope. FDA approved a new treatment for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options,

Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.

#TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor)